We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Decrement in Hemoglobin Levels Is Indicative of Colorectal Cancer

By LabMedica International staff writers
Posted on 19 Aug 2010
Long-term variation in blood hemoglobin (Hb) levels could detect subtle gastrointestinal bleeding in the early development of colorectal cancer (CRC). More...


Anemia, a common blood disorder, is characterized by low Hb levels, and has long been associated with those suffering from CRC. A sharp decrease in Hb levels was thought to be a symptom of colon cancer.

In a recent study carried out at the School of Public Health, Tel Aviv University (Tel Aviv, Israel), a total of 1,074 CRC cases aged 45–75 years that had been diagnosed with CRC and had normal Hb levels were frequency matched for age and sex with cancer-free individuals at a ratio of 10 controls per case. In this retrospective study, the scientists looked at data from each participant's blood tests over a ten-year period, retrieved from a computerized database.

The scientists have discovered that it is the continuous long-term decline that may announce the onset of cancer. Though hemoglobin levels may vary in every human being as a result of aging, a distinct trend was discovered among study participants who had been diagnosed with colorectal cancer during the study period. Approximately four years prior to their diagnoses, their blood tests began to show a continuous decline in Hb levels. A declining trend of more than 0.28 g/dL every six months over a four-year period was observed and it may serve as a warning of illness on the horizon. CRC patients were characterized by an on-going, long-term, logarithmic decrement in Hb levels. Such small changes within the normal Hb range could be missed by health providers, but automatically detected by computerized alert algorithms. Participants of the study with colorectal cancer experienced a sharp decline in Hb levels, but because the declines did not put them outside the normal range, no red flags were raised.

Inbal Goldshtein, a graduate student and lead author of the study said, "In practice, a doctor will look at the final results and see if the hemoglobin levels are within a normal range, but this is not accurate enough. It is important to look at the continuing trend of each individual. If a person experiences a consistent decline relative to his own average level, it may be cause for concern." The study was published in the July 2010 issue of the European Journal of Cancer Prevention.

The benefit of this screening process is that can be part of an average physical. Current testing for colorectal cancer is often expensive and unpleasant and there is also a very low compliance rate among patients. The next step is to create an algorithm, which will automatically detect suspicious declines in Hb levels, advising physicians to send their patients for further testing. More than 50,000 people in the U.S.A. will die from colon cancer in 2010, but better screening could significantly reduce those numbers.

Related Links:

Tel Aviv University




Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.